Proprotein convertase furin inhibits matrix metalloproteinase 13 in a TGFβ-dependent manner and limits osteoarthritis in mice

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Lin, Hilène ^a   Hay, Eric ^a   Latourte, Augustin ^a,b   Funck Brentano, Thomas ^a,b   Bouaziz, Wafa ^a   Ea, Hang Korng ^a,b   Khatib, Abdel Majid ^c   Richette, Pascal ^a,b   Cohen Solal, Martine ^a,b  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 1; ACVRL1 PROTEIN, MOUSE; COLLAGENASE 3; FURIN; MMP13 PROTEIN, MOUSE; SERINE PROTEINASE; TGFBR1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CHONDROCYTE; DRUG EFFECT; METABOLISM; MOUSE; OSTEOARTHRITIS;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; CHONDROCYTES; FURIN; MATRIX METALLOPROTEINASE 13; MICE; OSTEOARTHRITIS; PROPROTEIN CONVERTASES; RECEPTOR, TRANSFORMING GROWTH FACTOR-BETA TYPE I; TRANSFORMING GROWTH FACTOR BETA;

EID: 85049784554     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-28713-2     Document Type: Article

References (36)

1. Cross, M. et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann. Rheum. Dis. 73, 1323-1330 (2014).
2. Troeberg, L. &Nagase, H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim. Biophys. Acta. 1824, 133-145 (2012).
3. Arner, E. C. Aggrecanase-mediated cartilage degradation. Curr. Opin. Pharmacol. 2, 322-329 (2002).
4. Malfait, A. M., Liu, R. Q., Ijiri, K., Komiya, S. &Tortorella, M. D. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J. Biol. Chem. 277, 22201-22208 (2002).
5. Glasson, S. S. et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 434, 644-648 (2005).
6. Billinghurst, R. C. et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 99, 1534-1545 (1997).
7. Aigner, T., Zien, A., Gehrsitz, A., Gebhard, P. M. &McKenna, L. Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum. 44, 2777-2789 (2001).
8. Kevorkian, L. et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 50, 131-141 (2004).
9. Little, C. B. et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum. 60, 3723-3733 (2009).
10. Shen, J. et al. Deletion of the transforming growth factor beta receptor type II gene in articular chondrocytes leads to a progressive osteoarthritis-like phenotype in mice. Arthritis Rheum. 65, 3107-3119 (2013).
11. Bush, J. R. &Beier, F. TGF-beta and osteoarthritis\-The good and the bad. Nat. Med. 19, 667-669 (2013).
12. van der Kraan, P. M., Blaney Davidson, E. N., Blom, A. &van den Berg, W. B. TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor-Smads. Osteoarthritis Cartilage. 17, 1539-1545 (2009).
13. Yang, X. et al. TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J. Cell Biol. 153, 35-46 (2001).
14. van der Kraan, P. M. The changing role of TGFbeta in healthy, ageing and osteoarthritic joints. Nat. Rev. Rheumatol. 13, 155-163 (2017).
15. Blaney Davidson, E. N. et al. Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. J. Immunol. 182, 7937-7945 (2009).
16. Moldovan, F. et al. Modulation of collagenase 3 in human osteoarthritic cartilage by activation of extracellular transforming growth factor beta: role of furin convertase. Arthritis Rheum. 43, 2100-2109 (2000).
17. Ra, H. J. &Parks, W. C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596 (2007).
18. Milner, J. M., Rowan, A. D., Elliott, S. F. &Cawston, T. E. Inhibition of furin-like enzymes blocks interleukin-1alpha/oncostatin M-stimulated cartilage degradation. Arthritis Rheum. 48, 1057-1066 (2003).
19. Wang, P. et al. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. J. Biol. Chem. 279, 15434-15440 (2004).
20. Chen, C. G., Thuillier, D., Chin, E. N. &Alliston, T. Chondrocyte-intrinsic Smad3 represses Runx2-inducible matrix metalloproteinase 13 expression to maintain articular cartilage and prevent osteoarthritis. Arthritis Rheum. 64, 3278-3289 (2012).
21. van Caam, A. et al. Expression of TGFbeta-family signalling components in ageing cartilage: age-related loss of TGFbeta and BMP receptors. Osteoarthritis Cartilage. 24, 1235-1245 (2016).
22. van der Kraan, P. M., Goumans, M. J., Blaney Davidson, E. &ten Dijke, P. Age-dependent alteration of TGF-beta signalling in osteoarthritis. Cell Tissue Res. 347, 257-265 (2012).
23. Boeuf, S. et al. Regulation of aggrecanases from the ADAMTS family and aggrecan neoepitope formation during in vitro chondrogenesis of human mesenchymal stem cells. Eur. Cell Mater. 23, 320-332 (2012).
24. Creemers, J. W. &Khatib, A. M. Knock-out mouse models of proprotein convertases: unique functions or redundancy? Front. Biosci. 13, 4960-4971 (2008).
25. Mayer, G. et al. The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates. J. Biol. Chem. 283, 2373-2384 (2008).
26. Malfait, A. M. et al. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch. Biochem. Biophys. 478, 43-51 (2008).
27. Constam, D. B. Regulation of TGFbeta and related signals by precursor processing. Semin. Cell Dev. Biol. 32, 85-97 (2014).
28. Artenstein, A. W. &Opal, S. M. Proprotein convertases in health and disease. N. Engl. J. Med. 365, 2507-2518 (2011).
29. Latourte, A. et al. Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Ann. Rheum. Dis. 76, 748-755 (2017).
30. Lin, H. et al. Protective role of systemic furin in immune response-induced arthritis. Arthritis Rheum. 64, 2878-2886 (2012).
31. Bouaziz, W. et al. Loss of sclerostin promotes osteoarthritis in mice via beta-catenin-dependent and-independent Wnt pathways. Arthritis Res. Ther. 17, 24 (2015).
32. Hay, E. et al. Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation. J. Bone Miner. Res. 27, 1852-1863 (2012).
33. Kadri, A. et al. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum. 58, 2379-2386 (2008).
34. McAlindon, T. E., Driban, J. B. &Lo, G. H. Osteoarthritis year 2011 in review: clinical. Osteoarthritis Cartilage. 20, 197-200 (2012).
35. Kamekura, S. et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage. 13, 632-641 (2005).
36. Funck-Brentano, T. et al. Dkk-1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis Rheumatol. 66, 3028-3039 (2014).